RECRUITING

Shelter HArm Reduction Evaluation

Talk to us

Conditions

OverdoseHarm Reduction

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed study will use mixed methods research to examine overdose and other health-related impacts of harm reduction initiatives in NYC homeless shelters.

Official Title

Community-based Evaluation of a Novel, System-wide Harm Reduction Strategic Plan for People Experiencing Homelessness in New York City

Quick Facts

Study Start:2025-07-01
Study Completion:2026-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07170072

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult 18 year of age or older
  2. * Speak English
  3. * Is staying or has stayed in an NYC single-adult shelter that has implemented HRSP interventions
  4. * Report past-year drug use
  5. * Able and willing to provide consent
  6. * 18 years of age or older
  7. * Speak English
  8. * Works at an adult shelter service provider agency that implemented HRSP or received HRSP interventions (role may include case manager, security staff, shelter director, medical staff, organizational leadership)
  9. * Able and willing to provide consent
  10. * 18 years of age or older
  11. * Speak English
  12. * Works in a role in which they have key insight to the HRSP interventions, including planning and implementation (role may include homeless services administrator or other key stakeholder)
  13. * Able and willing to provide consent
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Bennett Allen, PhD
CONTACT
646-501-3708
Bennett.Allen@nyulangone.org
Kelly Doran, MD
CONTACT
212-263-5850
kelly.doran@nyulangone.org

Principal Investigator

Bennett Allen, PhD
PRINCIPAL_INVESTIGATOR
NYU Langone Health

Study Locations (Sites)

NYU Langone Health
New York, New York, 10016
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Bennett Allen, PhD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-01
Study Completion Date2026-09-30

Study Record Updates

Study Start Date2025-07-01
Study Completion Date2026-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Overdose
  • Harm Reduction